BioMarin agrees to buy Droia Ventures-backed Alesta Therapeutics for $275 million upfront
Reuters2026/08/18 13:56Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
- Droia Ventures portfolio company Alesta Therapeutics agreed to be acquired by BioMarin for USD 275 million upfront.
- Deal includes up to USD 215 million in development and regulatory milestones; BioMarin plans to fund the transaction with cash.
- Acquisition adds ALE1, an oral small-molecule in Phase 1/2a for hypophosphatasia, to BioMarin’s clinical-stage pipeline.
- Alesta will spin out non-ALE1 assets before closing; Alesta employees will transfer to the spinout, not BioMarin.
- BioMarin expects a modestly dilutive impact on 2026 results, excluding the upfront payment; closing is expected this quarter.
Disclaimer:
This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Droia Ventures published the original content used to generate this news brief on August 18, 2026, and is solely responsible for the information contained therein.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
JPMorgan trades Exail Technologies shares at EUR 124.61 during offer period
Reuters•2026/08/18 14:47
Luxury Homes Help Push Home Prices Higher in July -- Market Talk
Dow Jones•2026/08/18 14:46
MicroStrategy ends weekly bitcoin buying streak, keeps total holdings at 471,107 BTC
The Block•2026/08/18 14:45
York Water declares quarterly dividend of $0.228 per share
Reuters•2026/08/18 14:45
